Christopher Posner

Cara Therapeutics, Inc. (NASDAQ: CARA) released its financial results for the first quarter ended March 31, 2023, revealing revenues of $6.2 million, an increase of 29% compared to $4.8 million in Q1 2022. Q1 2023 Financial Results R&D expenses were $24.3 million for the three months ended...

Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 p.m. ET. The presentation will focus on the...